Eris Lifesciences and Biocon enter licensing agreement for insulin glargine
Eris Lifesciences, a pharmaceutical company, announced a licensing agreement with Biocon to market insulin glargine in India. In 3FY23, Eris plans to introduce insulin glargine.
Gilead Sciences to invest $405 million for MiroBio
Gilead Sciences and MiroBio, a privately held biotechnology company with headquarters in the UK, declared that they had signed a legally binding agreement under which Gilead will buy MiroBio for about $405 million in cash, subject to usual adjustments.
Azure Pharmaceuticals launched a high-quality generic range campaign
With the hashtag #encurewithazure, Azure Pharmaceuticals started a high-quality generic range campaign to minimize the expense of the patient’s prescriptions. At AZURE, the company’s commitment to safeguarding the health and welfare of its customers serves as its focus.
Enhertu from AstraZeneca and Daiichi receives historic FDA approval
Enhertu, developed by AstraZeneca and Daiichi Sankyo, has received a significant FDA approval, making it the first therapy specifically intended to treat metastatic or unresectable breast cancer that expresses low levels of HER2.
Sanofi invests more than $300 million in China's Innovent Biologics
According to Innovent Biologics, the biopharmaceutical company would receive HK$2.42 billion ($307.88 million) from Paris based Sanofi to work together on the development of two cancer medications in China.
Amgen places $3.7 billion bet on ChemoCentryx's rare disease drug
Amgen opted to acquire ChemoCentryx for $3.7 billion in order to obtain access to a potential game-changing anti-inflammatory medicine and surpass quarterly revenue projections for its therapy for bone disease.
Eli Lilly's migraine drug launch was slowed significantly, but rivals pounced
Emgality, an FDA-approved migraine
preventive medication, had some of Eli
Lilly’s most disappointing Q2 sales
numbers, with revenues reaching $157.5
million, up just 1% from the same quarter
last year.
